Early treatment with Radicava (edaravone), an approved therapy for amyotrophic lateral sclerosis (ALS), significantly reduced the risk of hospitalization, need for ventilatory support, or death compared with delaying treatment for six months. That’s according to analyses of data from Study 19 (NCT01492686), the Phase 3 clinical trial…

ALS patients have many wants and needs to make life a little easier and more comfortable. We know we can’t get everything, but it doesn’t hurt to try. So here it goes. Our bodies were made to move; to be active rather than passive. Lack of movement leads to…

An earlier start to noninvasive ventilation (NIV) could help to improve respiratory function and prolong survival for people with amyotrophic lateral sclerosis (ALS), according to a small clinical trial in Spain. While many of the study’s findings failed to reach statistical significance, the researchers believe the data still support…

A couple weeks ago, a friend asked me, “What are you going to do for your birthday?” “We’ll just have a family dinner and play games,” I said. “That’s all I want.” When my husband, Todd, and I were married, we might have gone on a weekend getaway or out…

An into-the-nose (intranasal) formulation of edaravone — the active ingredient in the amyotrophic lateral sclerosis (ALS) medication Radicava — may enhance the medication’s ability to reach brain tissue, according to a recent study. The formulation, which was made by packaging edaravone into tiny carriers called nanoparticles, was found…

Throughout our relationship, my late husband, Jeff, was the partner who most enjoyed taking care of people and things. He built wooden furniture and personal gifts, tended to flowers, and prepared meals from scratch. He got a great deal of satisfaction from going above and beyond for people. Jeff was…

Dimethyl fumarate (DMF) — an oral medication approved for multiple sclerosis — and H-151, an experimental treatment, can suppress inflammatory and abnormal immune pathways thought to be involved in sporadic amyotrophic lateral sclerosis (ALS). These are the findings of a study using immune cells from sporadic ALS patients…

Since my husband, Todd, is paralyzed from ALS, he can’t help with household chores and maintenance anymore. That puts much of it on me, but that’s also difficult for him because he loved many of those tasks. He enjoyed his career, which included work in marketing, finance, and manufacturing,…

Amylyx Pharmaceuticals Canada has entered into product listing agreements with Quebec and Ontario to publicly reimburse Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), which was recently approved for amyotrophic lateral sclerosis (ALS). The oral therapy, which is marketed in the U.S. as Relyvrio, has been added to the…